×

PCA3 Messenger RNA Species in Benign and Malignant Prostate Tissues

  • US 20080261228A1
  • Filed: 04/07/2008
  • Published: 10/23/2008
  • Est. Priority Date: 09/29/1999
  • Status: Active Grant
First Claim
Patent Images

1. A method of distinguishing differentially expressed PCA3 nucleic acids that indicate the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising the steps of:

  • (a) performing a nucleic acid amplification reaction, using spliced RNAs obtained from prostate cells contained in said sample as templates, to amplify PCA3 nucleic acid sequences across nucleotide positions 26 and 255 of SEQ ID NO;

    1 and nucleotide positions 26 and 27 of SEQ ID NO;

    2, whereby there are synthesized first and second amplification products in relative abundance dependent on the malignant and non-malignant status of prostate cells,wherein said first amplification product results from amplification of a first PCA3 mRNA that comprises an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO;

    1, andwherein said second amplification product results from amplification of a second PCA3 mRNA that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and

    (b) detecting one of said first and second amplification products independent of the other, thereby distinguishing differentially expressed PCA3 nucleic acids that indicate the status of prostate cells contained in said sample.

View all claims
  • 10 Assignments
Timeline View
Assignment View
    ×
    ×